Please assess the completion status of the following clinical trial:

Trial Title: Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Chronic hepatitis C infection of genotype 1~2. Therapy-naïve to interferon, pegylated interferon, and ribavirin~3. HCV viral load \> 100.000 IU/ml at screening~4. Liver biopsy or fibroscan within two years prior to screening that provides evidence of any degree of fibrosis or cirrhosis~5. Normal retinal finding on fundoscopy within 6 months prior to Day 1~6. Age 18 to 70 years~Exclusion criteria:~1. HCV of mixed genotype (1/2, 1/3, and 1/4) .~2. Patients who have been previously treated with at least one dose of any protease inhibitor~3. Evidence of liver disease due to causes other than chronic HCV infection~4. Positive for HIV-1 or HIV-2 antibodies~5. Hepatitis B virus (HBV) infection~6. Decompensated liver disease, or history of decompensated liver disease~7. Active malignancy or history of malignancy within the last 5 years~8. History of alcohol or drug abuse (except cannabis) within the past 12 months.~9. Body Mass Index \< 18 or \> 35 kg/m2.~10. Usage of any investigational drugs within 30 days prior to enrolment~11. Alpha fetoprotein value \>100ng/mL at screening;~12. Total bilirubin \> 1.5 x ULN with ratio of direct/indirect \> 1.~13. ALT or AST level \> 10 x ULN

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- short arm (Type: EXPERIMENTAL): patients to receive BI201335 with PegIFN/RBV for 12 wks followed by 12 weeks PegIFN/RBV with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)
- long arm (Type: EXPERIMENTAL): patients to receive BI201335 with PegIFN/RBV for 24 wks with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)

Based on this trial design, predict the completion outcome and termination type (if applicable).